Literature DB >> 24351895

Cross-sectional study on respiratory morbidity in workers after exposure to synthetic amorphous silica at five German production plants: exposure assessment and exposure estimates.

Peter Morfeld1, Dirk Taeger, Heike Mitura, Axel Bosch, Adrian Nordone, Reinhard Vormberg, Robert McCunney, Rolf Merget.   

Abstract

OBJECTIVES: Synthetic amorphous silicas (SASs) are nanostructured polymorphs of silicon dioxide. We compared two different exposure assessments.
METHODS: This study estimated cumulative exposure to inhalable SAS dust in 484 male workers from five German SAS-producing plants. Two procedures (P1 and P2) were applied. P1 was based on an expert assessment. P2 was a multiple exposure assessment (15 scenarios) anchored by a recent measurement series (1375 personal measurements of inhalable SAS dust concentration) and used expert assessments.
RESULTS: Cumulative exposure estimates for P1 averaged 56.9 mg/m·yrs (range, 0.1 to 419); for a selected P2 scenario, the mean was 31.8 mg/m·yrs (range, 0.4 to 480), (P < 0.0001). Averages varied between the 15 P2-scenarios from 12.6 to 109.6 mg/m·yrs. Different time trends for SAS concentrations were observed.
CONCLUSIONS: Both approaches suffer from considerable uncertainties that need to be considered in epidemiological studies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24351895     DOI: 10.1097/JOM.0000000000000055

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  2 in total

1.  Surface Treatment With Hydrophobic Coating Reagents (Organosilanes) Strongly Reduces the Bioactivity of Synthetic Amorphous Silica in vitro.

Authors:  Martin Wiemann; Antje Vennemann; Tobias B Schuster; Jürgen Nolde; Nils Krueger
Journal:  Front Public Health       Date:  2022-06-21

2.  Extended Investigation of Exposure to Respirable Synthetic Amorphous Silica Dust and Its Potential Impact on Non-malignant Respiratory Morbidity.

Authors:  Mei Yong; Peter Morfeld; Robert McCunney
Journal:  Front Public Health       Date:  2022-05-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.